DCTH Delcath Systems Inc SURGICAL & MEDICAL INSTRUMENTS & APPARATUS Best Medical Devices Stocks 2026 →

Delcath Systems (DCTH) Stock: Buy, Sell, or Hold?

$19.91
-0.64 (-3.14%) ▼
5d: -1.8% 30d: +41.37% 90d: +18.06%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (14%)
Quality Score
36/100
Position
EXTENDED
30-Day Fair Range
$13.48 – $17.85
Position: EXTENDED
Forward P/E & Valuation
75.4x CHEAP
vs 197.4x historical avg
Wall Street Target
$28.60
+39.2% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$14.20 / $22.51
Trend: Uptrend
💡Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
⏸️ WAIT FOR BETTER ENTRY: DCTH is 11.5% above its trading range ($17.85). Market expects -27.4% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.

Get Alerted When DCTH Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.
100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading chart...

Loading historical data...

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

0% (Stagnation) 50% (Hyper Growth)
EST. PRICE IN 2031
$13.27
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$8.24
Trading above historical range

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.

In-depth Analysis How we analyze

Valuation Analysis: DCTH is currently trading at $19.91, which is considered extended relative to its 30-day fair value range of $13.48 to $17.85. From a valuation perspective, the stock is trading at a discount (Forward PE: 75.4) compared to its historical average (197.4). Remarkably, the market is currently pricing in an annual earnings decline of 27.4% over the next few years. This pessimistic expectation contrasts with the company's recent 750.0% earnings growth, suggesting potential undervaluation if the company simply maintains stability.

Technical Outlook: Technically, DCTH is in a uptrend. Immediate support is located at $14.20, while resistance sits at $22.51. Short-term momentum is weak, with the stock down 3.1% recently.

Market Sentiment: DCTH scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $28.60 (+39.2%). Current signals suggest waiting for a better entry point before initiating new positions.

Quick Decision Summary

Current Position EXTENDED
Historical Trading Range $13.48 - $17.85
Company Quality Score 36/100 (SELL)
Volume Confirmation HIGH
Confidence Score 14.3%

Trading Range & Key Levels

30-Day Trading Range $13.48 - $17.85
Current vs Trading Range EXTENDED
Support Level $14.20
Resistance Level $22.51
Current Trend Uptrend
Technical data as of Nov 16, 2026

Institutional Signals, 13F Whale Activity & Setup Structure

Quantitative Research Feed
Phase & Gamma Walls BREAKOUT
Days in Phase: 66d (53% conf)
Put Wall / Support: $18 (59 OI)
Call Wall / Resist: $23 (524 OI)
Technical Setup Structure MONITORING
Absorption: Inactive (CMF 0.14)
Pullback / Drawdown: -5.6% from 52W High
Consolidation: Trending (ADX 34.3)

Quantitative Signal Breakdown

  • BEARISH: Price significantly overextended (+11.5% above its trading range)
  • BEARISH: Weak technical setup (0/100)
  • BULLISH: High volume confirmation
  • BEARISH: Downward momentum (-3.1%)
  • BULLISH: Trading 39.2% below Wall St target ($28.60)
  • WARNING: Composite score 36/100 in the bottom quintile — this cohort historically lags the market

Fundamental Context

Forward P/E (Next Year Est.) 75.41
Wall Street Target $28.60 (+39.2%)
Revenue Growth (YoY) 70.7%
Earnings Growth (YoY) 750.0%
Profit Margin 6.0%
Valuation Discount vs History -27.4% cheaper
PE vs Historical 75.4 vs 197.4 CHEAP
Market-Implied Price Targets If current PE multiple persists
Implied Growth (YoY): -27.4% (market-implied from PE analysis)
1-Year Target $18.50 (-10%)
2-Year Target $16.65 (-19%)
3-Year Target $14.98 (-27%)
3-Yr Target (if PE normalizes) (PE: 75→197) $39.21 (+91%)
3-Year Scenarios Using analyst projected EPS growth
Bull: (PE: 75.4, Growth: 36.3%) $51.98 (+153%)
Base: (SPY PE: 19.9, Growth: 36.3%) $13.69 (-33%)
Bear: (PE: 16.9, Growth: 36.3%) $11.64 (-43%)
💡 Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 75.4 to 197.4
Stabilization Target: $53.79 (+161.8%)
PE Expansion Potential: +161.8%
Share DCTH Analysis

Share this live DCTH analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.

bloggers & journalists: you are free to use our charts with attribution.

Reddit & Retail Trader Sentiment (DCTH)

Bullish 1 Retail Mentions
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Nov 16, 2026
Daily AI digest
AI Retail Discussion Summary: Bullish sentiment on StockTwits regarding $DCTH's expansion into hospital systems with multiple locations, as opposed to academic centers.
Key Retail Themes: Expansion into hospital systems Many locations and procedures
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams. View All Trending Reddit & WSB Stocks →
Last updated: November 16, 2026 1:47 PM ET
Data refreshes hourly during market hours. Next update: 2:47 PM
🔥 Top Stocks Breaking Out Now
Ticker Score Recommendation Change %
Technical Signals Check
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL

Unlock Insider Activity

See real-time buying/selling by company executives for DCTH.

Create Free Account

Already have an account? Log In

Top Rated Medical Devices Stocks

Top-rated stocks in Medical Devices by analyst ratings.

Stock Analyst Consensus Analyst Target Tradestie Score
DXCM
DexCom Inc
STRONG BUY
29 analysts
$99 54 HOLD
ABT
Abbott Laboratories
STRONG BUY
28 analysts
$119 48 HOLD
SYK
Stryker Corporation
STRONG BUY
30 analysts
$339 44 HOLD
EW
Edwards Lifesciences Corp
STRONG BUY
30 analysts
$113 32 SELL
GEHC
GE HealthCare Technologi…
BUY
22 analysts
$88 33 SELL
Live Trades
From trading groups
Loading trades...
View All Live Trades See Trader Consensus & Signals